IDEXX Laboratories, Inc. (NASDAQ:IDXX) Holdings Lifted by UniSuper Management Pty Ltd

UniSuper Management Pty Ltd grew its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 16.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 14,801 shares of the company’s stock after purchasing an additional 2,045 shares during the period. UniSuper Management Pty Ltd’s holdings in IDEXX Laboratories were worth $7,992,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of IDXX. Wellington Management Group LLP grew its position in IDEXX Laboratories by 2.0% in the 3rd quarter. Wellington Management Group LLP now owns 3,486 shares of the company’s stock worth $1,524,000 after purchasing an additional 67 shares during the last quarter. Dynamic Advisor Solutions LLC boosted its holdings in shares of IDEXX Laboratories by 14.1% in the fourth quarter. Dynamic Advisor Solutions LLC now owns 1,255 shares of the company’s stock valued at $674,000 after acquiring an additional 155 shares in the last quarter. OneAscent Financial Services LLC bought a new position in shares of IDEXX Laboratories in the fourth quarter valued at approximately $221,000. CX Institutional bought a new position in shares of IDEXX Laboratories in the fourth quarter valued at approximately $228,000. Finally, Everhart Financial Group Inc. boosted its holdings in shares of IDEXX Laboratories by 16.9% in the fourth quarter. Everhart Financial Group Inc. now owns 912 shares of the company’s stock valued at $506,000 after acquiring an additional 132 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on IDXX shares. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. William Blair restated an “outperform” rating on shares of IDEXX Laboratories in a research report on Tuesday, April 9th. Morgan Stanley cut their target price on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating for the company in a research report on Tuesday, May 14th. Stifel Nicolaus cut their target price on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a research report on Monday, June 24th. Finally, Barclays cut their target price on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a research report on Thursday, May 2nd. Four analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $586.63.

Insider Activity at IDEXX Laboratories

In related news, Director Bruce L. Claflin sold 200 shares of the business’s stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $540.80, for a total transaction of $108,160.00. Following the completion of the transaction, the director now owns 161 shares in the company, valued at $87,068.80. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 2.11% of the company’s stock.

IDEXX Laboratories Stock Performance

NASDAQ IDXX traded down $4.88 during midday trading on Tuesday, hitting $470.41. The company had a trading volume of 398,355 shares, compared to its average volume of 474,107. IDEXX Laboratories, Inc. has a fifty-two week low of $372.50 and a fifty-two week high of $583.39. The stock has a market cap of $38.85 billion, a price-to-earnings ratio of 45.54, a P/E/G ratio of 3.83 and a beta of 1.32. The company has a quick ratio of 1.16, a current ratio of 1.57 and a debt-to-equity ratio of 0.40. The firm has a fifty day simple moving average of $498.03 and a two-hundred day simple moving average of $518.59.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Wednesday, May 1st. The company reported $2.81 EPS for the quarter, topping the consensus estimate of $2.68 by $0.13. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. The company had revenue of $964.10 million during the quarter, compared to analysts’ expectations of $965.43 million. Equities analysts forecast that IDEXX Laboratories, Inc. will post 11 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.